Have spoken to Peak Asset manager. It’s a good raise. Very...

Have spoken to Peak Asset manager. It’s a good raise. Very aggressive and short expiry on options is encouraging those participating to execute (they have confidence share price will be in a position where it is worth executing CDTOA) which results in additional revenue for Castle.

I wasn’t happy seeing the announcement this morning knowing Castle already has cash in the bank and the TH came out of left field - but feel much more settled now knowing the direction that management is targeting.

Results will likely be out on Monday. Market wide results have been getting sold into with little positive macro momentum. Placement will likely be oversubscribed - raise is a minimum $2M “with ability to take oversubscriptions at the discretion of the company.” It will show CDT is moving faster than many think behind the scenes and have additional capital behind them as opposed to the situation of getting sold into with negative market sentiment and then having to raise sub 2c worst case.

The assay results being released will be incorporated into a maiden JORC 2012 MRE which is scheduled for end of Q1 23.

Lots of news flow to come during the March 2023 quarter across all projects, as will be reflected soon

GLTA